Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Updated from v3.0.1 to v3.0.2 and removed the 'Back to Top' control.
    Difference
    0.3%
    Check dated 2025-09-14T18:42:44.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.3%
    Check dated 2025-09-07T13:05:25.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name, location details, and specific drug information for Fruquintinib, HMPL-013, and sintilimab, while removing extensive disease categories and previous location terms.
    Difference
    3%
    Check dated 2025-08-31T03:45:29.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T20:27:52.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.1%
    Check dated 2025-08-09T16:29:44.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.
    Difference
    2%
    Check dated 2025-08-02T14:15:19.000Z thumbnail image

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.